Document:

EX-10.1

 Exhibit 10.1 

EMPLOYMENT AGREEMENT 
 THIS
EMPLOYMENT AGREEMENT by and between MeadWestvaco Corporation, a Delaware corporation (the “Company”), and Robert K. Beckler (the “Executive”) is dated as of March 3, 2014. 

RECITALS 
 WHEREAS,
the Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company and its shareholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the
possibility, threat or occurrence of a Change of Control (as defined below) of the Company. The Board believes it is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by a
pending or threatened Change of Control, to encourage the Executive’s full attention and dedication to the Company currently and in the event of any threatened or pending Change of Control, and to provide the Executive with compensation and
benefits arrangements upon a Change of Control which ensure that the compensation and benefits expectations of the Executive will be satisfied and which are competitive with those of other corporations. Therefore, in order to accomplish these
objectives, the Board caused the Company to enter into this Agreement. 
 NOW, THEREFORE, IT IS HEREBY AGREED as follows: 

1. Change of Control. For the purpose of this Agreement, a “Change of Control” shall mean: 

(a) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”)) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (i) the then outstanding shares of common stock of
the Company (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company
Voting Securities”); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control: (i) any acquisition directly from the Company, (ii) any acquisition by the Company,
(iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any corporation pursuant to a transaction which complies
with clauses (i), (ii) and (iii) of subsection (c) of this Section 1; or 
 (b) Individuals who, as of the date hereof,
constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose election, or nomination for
election by the Company’s shareholders, was approved by a vote of at least a 

 
majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such
individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a
Person other than the Board; or 
 (c) Consummation of a reorganization, merger, statutory share exchange or consolidation or similar
corporate transaction involving the Company or any of its subsidiaries, or a sale or other disposition of all or substantially all of the assets of the Company (as determined under applicable Delaware law) (each, a “Business Combination”),
in each case, unless, following such Business Combination, (i) all or substantially all of the individuals and entities that were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting
Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 60% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities
entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or
substantially all of the Company’s assets either directly or through one or more subsidiaries) (the “Resulting Corporation”) in substantially the same proportions as their ownership, immediately prior to such Business Combination of
the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding the Resulting Corporation and its affiliates or any employee benefit plan (or related trust) of the Resulting
Corporation and its affiliates) beneficially owns, directly or indirectly, 20% or more of, respectively, the then-outstanding shares of common stock of the Resulting Corporation or the combined voting power of the then outstanding voting securities
of the Resulting Corporation except to the extent that such ownership existed with respect to the Company prior to the Business Combination, and (iii) at least a majority of the members of the board of directors of the Resulting Corporation
(the “Resulting Board”) were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination; or 

(d) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company. 

2. Certain Other Definitions. (a) “Affiliated Companies” shall include any company controlled by, controlling or under
common control with the Company. 
 (b) The “Change of Control Period” shall mean the period commencing on the date hereof and
ending on the second anniversary of the date hereof, as subsequently extended as described below. The Change of Control Period shall be automatically extended for successive one-year periods unless the Company notifies the Executive in writing, at
least one year prior to the end of the then current term, that the Change of Control Period will not be extended; provided, however, that the Change of Control Period and this Agreement shall terminate if the Executive’s employment with the
Company terminates for any reason before a Change of Control, except as provided in Section 2(c) and Section 13(f) below. 

  
 2 

 (c) The “Effective Date” shall mean the first date during the Change of Control Period
on which a Change of Control occurs. Anything in this Agreement to the contrary notwithstanding, if a Change of Control occurs within 30 days after the Executive’s termination of employment and if the Executive’s employment with the
Company is terminated prior to the date on which the Change of Control occurs, and if it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably
calculated to effect a Change of Control or (ii) otherwise arose in connection with or anticipation of a Change of Control, then for all purposes of this Agreement the “Effective Date” shall mean the date immediately prior to the date
of such termination of employment. 
 (d) “Merger of Equals Period” shall mean (i) any portion of the Employment Period (as
defined in Section 3) up to and including the first anniversary of the Effective Date during which the conditions set forth in the next sentence are met, and (ii) if the conditions set forth in the next sentence are met on the first
anniversary of the Effective Date, the portion of the Employment Period that follows the first anniversary of the Effective Date. The conditions referred to in the preceding sentence are that (A) the Change of Control that occurred on the
Effective Date was a Business Combination, and (B) at the time in question, (I) at least 50% of the members of the Resulting Board are individuals who were members of the Incumbent Board (as defined in Section 1(b)) at the time of the
execution of the initial agreement, or of the action of the Board, providing for such Business Combination, and (II) either (x) the position of chief executive officer of the Resulting Corporation is occupied by an individual who was employed
by the Company immediately before such Business Combination, or (y) a majority of the leadership positions reporting directly to the chief executive officer of the Resulting Corporation are occupied by individuals who were employed by the
Company immediately before such Business Combination. 
 (e) The “Multiple” means two. 

(f) “Peer Executives” shall mean, at any given time, the other persons employed by the Company or any of the Affiliated Companies
who either (1) were, immediately before the Effective Date, party to agreements with the Company substantially in the form of this Agreement (without regard to the definition of “Multiple”) or (2) are similarly situated
executives who were employed, before the Effective Date, by the other party to the transaction constituting a Change of Control hereunder. 

(g) “Relevant Time” shall mean immediately before the Effective Date, except to the extent otherwise provided in
Section 4(b)(ix). 
 3. Employment Period. The Company hereby agrees to continue the Executive in its employ, subject to the
terms and conditions of this Agreement, for the period commencing on the Effective Date and ending on the second anniversary of such date (the “Employment Period”). The Employment Period shall terminate upon the termination of the
Executive’s employment for any reason. 
 4. Terms of Employment. (a) Position and Duties. (i) During the Employment
Period, there shall be no material reduction in the Executive’s position, authority, 

  
 3 

 
duties, responsibilities or salary grade as compared to those held, exercised and assigned to the Executive at the Relevant Time. Notwithstanding the foregoing, during any Merger of Equals
Period, the Executive’s position may be changed in a manner violating the requirements of this Section 4(a)(i), provided that the Executive continues to have responsibilities and authority that are, in the aggregate, comparable to those
held by the Executive at the Relevant Time; and provided, further, that neither a reduced scope of the Executive’s responsibilities resulting from the fact that the Change of Control has created a larger organization, nor a change in the
Executive’s title and reporting responsibilities, shall be the sole basis for determining whether the requirements of this sentence are met. 

(ii) During the Employment Period, the Executive’s services shall be performed at the location where the Executive was employed
immediately preceding the Effective Date, or at any other location that does not result in the Executive’s commuting distance from the Executive’s residence being increased by more than 40 miles; provided, that if the Executive
voluntarily changes his residence after the Effective Date, then a new work location shall not be considered to have increased the Executive’s commuting distance by more than 40 miles unless such an increase both (1) occurs in relation to
the Executive’s new residence and (2) would have occurred even if the Executive had not changed his residence. 
 (iii) During
the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote reasonable attention and time during normal business hours to the business and affairs of the Company and,
to the extent necessary to discharge the responsibilities assigned to the Executive hereunder, to use the Executive’s reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period it shall not
be a violation of this Agreement for the Executive to (A) serve on corporate, civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions and (C) manage personal
investments, so long as such activities do not significantly interfere with the performance of the Executive’s responsibilities as an employee of the Company in accordance with this Agreement. It is expressly understood and agreed that to the
extent that any such activities have been conducted by the Executive prior to the Effective Date, the continued conduct of such activities (or the conduct of activities similar in nature and scope thereto) subsequent to the Effective Date shall not
thereafter be deemed to interfere with the performance of the Executive’s responsibilities to the Company. 
 (b) Compensation.

 (i) Base Salary. During the Employment Period, the Executive shall receive an annual base salary (“Annual Base Salary”)
which shall be not less than the Executive’s annual base salary from the Company and the Affiliated Companies as in effect immediately before the Effective Date, except as otherwise permitted below in this Section 4(b)(i). Any increase in
Annual Base Salary during the Employment Period shall not serve to limit or reduce any other obligation to the Executive under this Agreement, and except as provided in the next sentence, the Annual Base Salary shall not be reduced during the
Employment Period. Notwithstanding the foregoing during any Merger of Equals Period the Annual Base Salary may be decreased if all the annual base salaries of all of the Peer Executives are decreased by the same or a greater percentage. The term
Annual Base Salary as utilized in his Agreement shall refer to Annual Base Salary as increased or decreased to the extent permitted by this Section 4(b)(i). 

  
 4 

 (ii) Incentive Compensation Opportunities. In addition to the Annual Base Salary, the
Executive shall be granted, during the Employment Period, cash-based and equity-based awards representing the opportunity to earn incentive compensation on terms and conditions no less favorable to the Executive, in the aggregate, than those
provided generally at any time after the Effective Date to the Peer Executives or, if more favorable to the Executive, than those provided by the Company and the Affiliated Companies for the Executive immediately before the Effective Date. In
determining whether the Executive’s incentive compensation opportunities during the Employment Period meet the requirements of the preceding sentence, there shall be taken into account all relevant terms and conditions, including, without
limitation and to the extent applicable, the potential value of such awards at minimum, target and maximum performance levels, and the difficulty of achieving the applicable performance goals. 

(iii) Savings and Retirement Plans. During the Employment Period, the Executive shall be entitled to participate in all savings and
retirement plans, practices, policies and programs applicable generally to the Peer Executives, on comparable terms and conditions, but in no event shall such plans, practices, policies and programs provide the Executive with savings opportunities
and retirement benefits, in each case, less favorable, in the aggregate, to the Executive than those provided by the Company and the Affiliated Companies to the Executive at the Relevant Time. 

(iv) Welfare Benefit Plans. During the Employment Period, the Executive and/or the Executive’s family, as the case maybe, shall
be eligible for participation in and shall receive all benefits under welfare benefit plans, practices, policies and programs provided by the Company and the Affiliated Companies (including, without limitation, medical, prescription, dental,
disability, employee life, group life, accidental death and travel accident insurance plans and programs) (collectively, “Welfare Benefits”) to the extent applicable generally to the Peer Executives, on comparable terms and conditions, but
in no event shall such Welfare Benefits for the Executive be less favorable, in the aggregate, to the Executive than the Welfare Benefits provided by the Company and the Affiliated Companies to the Executive at the Relevant Time. 

(v) Expenses. During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable
expenses incurred by the Executive in accordance with the policies, practices and procedures as in effect for the Peer Executives; provided, that such policies, practices and procedures shall not be less favorable to the Executive than those
provided by the Company and the Affiliated Companies to the Executive at the Relevant Time. 
 (vi) Fringe Benefits. During the
Employment Period, the Executive shall be entitled to fringe benefits, including, without limitation, tax and financial planning services, payment of club dues, and, if applicable, use of an automobile and payment of related expenses, as in effect
for Peer Executives; provided, that such fringe benefits shall not be less favorable, in the aggregate, to the Executive than those provided by the Company and the Affiliated Companies to the Executive at the Relevant Time. 

  
 5 

 (vii) Office and Support Staff. During the Employment Period, the Executive shall be
entitled to an office or offices of a size and with furnishings and other appointments, and to personal secretarial and other assistance, as in effect for the Peer Executives; provided, that such facilities and assistance shall not be less
favorable, in the aggregate, to the Executive than those provided by the Company and the Affiliated Companies to the Executive at the Relevant Time. 

(viii) Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans,
policies, programs and practices of the Company and the Affiliated Companies as in effect for the Peer Executives; provided, that such plans, policies, programs and practices shall not be less favorable to the Executive than those provided by the
Company and the Affiliated Companies to the Executive at the Relevant Time. 
 (ix) Changes During Merger of Equals Period.
Notwithstanding the foregoing, during any Merger of Equals Period, the incentive compensation opportunities and benefits provided to the Executive may be changed in a manner violating the requirements of any of Sections 4(b)(ii)-(viii), if such
changes apply to Peer Executives generally. Following any such change, the “Relevant Time” for determining whether such requirements continue to be satisfied with respect to the particular benefit that has been changed shall be immediately
following the effectiveness of such change. 
 5. Termination of Employment. 

(a) Death or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the
Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the Employment Period (pursuant to the definition of Disability set forth below), it may give to the Executive written notice in
accordance with Section 13(b) of this Agreement of its intention to terminate the Executive’s employment. In such event, the Executive’s employment with the Company shall terminate effective on the 30th day after receipt of such
notice by the Executive (the “Disability Effective Date”), provided that, within the 30 days after such receipt, the Executive shall not have returned to full-time performance of the Executive’s duties. For purposes of this Agreement,
“Disability” shall mean the absence of the Executive from the Executive’s duties with the Company on a full-time basis for 180 consecutive business days as a result of incapacity due to mental or physical illness which is determined
to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive’s legal representative. 

(b) Cause. The Company may terminate the Executive’s employment during the Employment Period for Cause or without Cause. For
purposes of this Agreement, “Cause” shall mean: 
 (i) the willful and continued failure of the Executive to
perform substantially the Executive’s duties with the Company or one of its affiliates 

  
 6 

 
(other than any such failure resulting from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to the Executive by the Board or the
Chief Executive Officer of the Company which specifically identifies the manner in which the Board or Chief Executive Officer believes that the Executive has not substantially performed the Executive’s duties, or 

(ii) the willful engaging by the Executive in illegal conduct or gross misconduct; or 

(iii) a clearly established violation by the Executive of the Company’s Code of Conduct that is materially and
demonstrably injurious to the Company. 
 For purposes of this provision, no act or failure to act, on the part of the Executive, shall be considered
“willful” unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive’s action or omission was in the best interests of the Company. Any act, or failure to act, based upon
authority given pursuant to a resolution duly adopted by the Board or upon the instructions of the Chief Executive Officer or a senior officer of the Company or based upon the advice of counsel for the Company shall be conclusively presumed to be
done, or omitted to be done, by the Executive in good faith and in the best interests of the Company. 
 (c) Good Reason. The
Executive’s employment may be terminated by the Executive for Good Reason or without Good Reason. For purposes of this Agreement, “Good Reason” shall mean: 

(i) A material diminution in the Executive’s Annual Base Salary (other than as permitted under Section 4(b)(i)
hereof); 
 (ii) A material diminution in the Executive’s authority, duties, or responsibilities (other than as
permitted by Section 4(a) hereof); 
 (iii) A material change in the geographic location at which the Executive must
perform services for the Company in violation of Section 4(a)(ii) hereof; or 
 (iv) Any other action or inaction that
constitutes a material breach by the Company of this Agreement, including any failure of the Company to comply with and satisfy Section 11(c) of this Agreement. 

(d) Notice of Termination; Opportunity to Cure. Any termination by the Company for Cause, or by the Executive for Good Reason, shall be
communicated by Notice of Termination to the other party hereto given in accordance with Section 13(b) of this Agreement. For purposes of this Agreement, a “Notice of Termination” means a written notice which (i) indicates the
specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the
provision so indicated and (iii) specifies the Date of Termination (as defined below). If the Executive is terminating 

  
 7 

 
employment for Good Reason, (i) the Executive shall give the Company the Notice of Termination not less than 60 days following the event giving rise to the Executive’s Good Reason
termination, and (ii) the Company shall have a period of 30 days after receiving the Notice of Termination to remedy the action or inaction on which Good Reason is based. If the Company fails to remedy the action or inaction on which Good
Reason is based within such 30-day period, the Executive may terminate his or her employment for Good Reason within 30 days after the end of the cure period. 

(e) Date of Termination. “Date of Termination” means (i) if the Executive’s employment is terminated by reason of
the Executive’s death, the date of death, (ii) if the Executive’s employment is terminated by reason of Disability, the Disability Effective Date, and (iii) if the Executive’s employment is otherwise terminated by the
Company or by the Executive, the date of receipt of the Notice of Termination or any date within 30 days thereafter that is specified in the Notice of Termination. 

6. Obligations of the Company upon Termination. (a) Good Reason, Other Than for Cause, Death or Disability. If, during the
Employment Period, the Company shall terminate the Executive’s employment other than for Cause or Disability or the Executive shall terminate employment for Good Reason: 

(i) The Company shall pay to the Executive, in a lump sum cash payment within 30 days after the Date of Termination, the
aggregate of the following amounts: 
 (a) The sum of (1) the Executive’s Annual Base Salary through the Date of
Termination to the extent not theretofore paid, (2) the product of (x) the average of the annual cash bonuses payable to the Executive under the bonus programs of the Company and the Affiliated Companies during the period of three years
ending on the Effective Date, or such shorter period during which the Executive has been employed by the Company (disregarding for this purpose any deferral of the payment of any such bonuses) (the “Average Incentive Compensation”) and
(y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of which is 365 and (3) any accrued vacation pay, in each case to the extent not theretofore paid
(the sum of the amounts described in clauses (1), (2), and (3) shall be hereinafter referred to as the “Accrued Obligations”), and 

(b) The amount equal to the product of (1) the Multiple, times (2) the sum of (x) the Executive’s Annual
Base Salary and (y) the Average Incentive Compensation. 
 (ii) Unless the Date of Termination occurs during the Merger
of Equals Period, all benefits accrued through the Date of Termination by the Executive under the Company’s qualified defined benefit retirement plan (the “Retirement Plan”) and any excess defined benefit retirement plan in which the
Executive participates, but not under the Mead Corporation Supplemental Executive Retirement Plan or any successor plan (the “Excess Plan”), that are not vested as of the Date of Termination shall be fully vested and shall be paid in
accordance with the payment terms of the applicable plan; provided 

  
 8 

 
that, to the extent such benefits may not be provided under the Retirement Plan, they shall instead be provided under the Excess Plan and shall be paid at the time and in the form provided under
the Excess Plan. Unless the Date of Termination occurs during the Merger of Equals Period, the Company shall also pay the Executive, in a lump sum cash payment within 30 days after the Date of Termination an amount equal to the excess of: 

(a) The actuarial equivalent of the benefit under the Retirement Plan (utilizing actuarial assumptions no less favorable to
the Executive than those in effect under the Retirement Plan immediately prior to the Effective Date) and the Excess Plan that the Executive would have received if the Executive’s employment had continued for three years after the Date of
Termination, and if all of the Executive’s accrued benefits were fully vested and the Executive’s compensation for each of those three years had been equal to the sum of (I) the Executive’s Annual Base Salary and (II) the average
of the annual cash bonuses payable to the Executive under the bonus programs of the Company and the Affiliated Companies during the period of three years ending on the Effective Date, or such shorter period during which the Executive has been
employed by the Company (disregarding for this purpose any deferral of the payment of any such bonuses), over 
 (b) The
actuarial equivalent of the Executive’s actual benefit (paid or payable) under the Retirement Plan and the Excess Plan (including any benefits that vest pursuant to the first sentence of this subsection (ii)) as of the Date of Termination. 

(iii) The Company shall pay the Executive a lump sum cash payment within 30 days following the Executive’s Date of
Termination equal to the cost of health coverage for the number of years equal to the Multiple, based on the monthly COBRA cost of such coverage under the Company’s health plan pursuant to Section 4980B of the Internal Revenue Code of
1986, as amended (the “Code”) on the Date of Termination. 
 (iv) The Company shall, at its sole expense as
incurred, provide the Executive with outplacement services the scope and provider of which shall be reasonable and consistent with industry practice for similarly situated executives and consistent with Section 12(b) of this Agreement. 

(v) To the extent not theretofore paid or provided, the Company shall timely pay or provide the Executive with any Other
Benefits (as defined in Section 7) in accordance with the terms of the applicable plans. 
 Notwithstanding the foregoing, except with respect to
payments and benefits under Sections 6(a)(i)(a)(1), 6(a)(i)(a)(3) and 6(a)(v), all payments and benefits to be provided under this Section 6(a) shall be subject to the Executive’s execution and non-revocation of a release substantially in
the form attached hereto as Exhibit A. To the extent required by Section 409A of the Code, if payments and benefits subject to a release could be paid in two taxable years pursuant to the terms of this Section 6(a), such payments
and benefits shall be paid in the later taxable year. 

  
 9 

 (b) Death. If the Executive’s employment is terminated by reason of the
Executive’s death during the Employment Period, the Company shall provide the Executive’s estate or beneficiaries with the Accrued Obligations and the timely payment or delivery of the Other Benefits, and shall have no other severance
obligations under this Agreement. The Accrued Obligations shall be paid to the Executive’s estate or beneficiary, as applicable, in a lump sum in cash within 30 days following the Date of Termination. With respect to the provision of Other
Benefits, the term Other Benefits as utilized in this Section 6(b) shall include, without limitation, and the Executive’s estate and/or beneficiaries shall be entitled to receive, benefits at least equal to the most favorable benefits
provided by the Company and the Affiliated Companies to the estates and beneficiaries of the Peer Executives under such plans, programs, practices and policies relating to death benefits, if any, as in effect with respect to the Peer Executives and
their beneficiaries at the Relevant Time or, if more favorable to the Executive’s estate and/or the Executive’s beneficiaries, on the Date of Termination. 

(c) Disability. If the Executive’s employment is terminated by reason of the Executive’s Disability during the Employment
Period, the Company shall provide the Executive with the Accrued Obligations and the timely payment or delivery of the Other Benefits, and shall have no other severance obligations under this Agreement. Accrued Obligations shall be paid to the
Executive in a lump sum in cash within 30 days following the Date of Termination. With respect to the provision of Other Benefits, the term Other Benefits as utilized in this Section 6(c) shall include, and the Executive shall be entitled after
the Disability Effective Date to receive, disability and other benefits at least equal to the most favorable of those generally provided by the Company and the Affiliated Companies to disabled executives and/or their families in accordance with such
plans, programs, practices and policies relating to disability, if any, as in effect generally with respect to the Peer Executives and their families at the Relevant Time or, if more favorable to the Executive and/or the Executive’s family, on
the Date of Termination. 
 (d) Cause; Other than for Good Reason. If the Executive’s employment is terminated for Cause during
the Employment Period, the Company shall provide to the Executive the Executive’s Annual Base Salary through the Date of Termination, and the Other Benefits, in each case, to the extent theretofore unpaid, and shall have no other severance
obligations under this Agreement. If the Executive voluntarily terminates employment during the Employment Period, excluding a termination for Good Reason, the Company shall provide to the Executive the Accrued Obligations and the timely payment or
delivery of the Other Benefits, and shall have no other severance obligations under this Agreement. In such case, all the Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days following the Date of Termination. 

7. Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit the Executive’s continuing or future participation
in any plan, program, policy or practice provided by the Company or any of the Affiliated Companies and for which the Executive may qualify, nor, subject to Section 13(f), shall anything herein limit or otherwise affect such rights as the
Executive may have under any contract or agreement with the Company or any of the Affiliated Companies. Amounts that are vested benefits or that the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any
contract or agreement with the Company or any of the Affiliated Companies at or subsequent to the Date of Termination (“Other Benefits”) shall be payable in accordance with such plan, policy, practice or

  
 10 

 
program or contract or agreement except as explicitly modified by this Agreement. Notwithstanding the foregoing, if the Executive receives payments and benefits pursuant to Section 6(a) of
this Agreement, the Executive shall not be entitled to any severance pay or benefits under any severance plan, program or policy of the Company and the Affiliated Companies, unless otherwise specifically provided therein in a specific reference to
this Agreement. 
 8. Full Settlement. The Company’s obligation to make the payments provided for in this Agreement and
otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action that the Company may have against the Executive or others. In no event shall the Executive be
obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement and such amounts shall not be reduced whether or not the Executive obtains other
employment. The Company agrees to pay as incurred, to the full extent permitted by law, all legal fees and expenses which the Executive may reasonably incur as a result of any contest (regardless of the outcome thereof) by the Company, the Executive
or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest by the Executive about the amount of any payment pursuant to this
Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Code. Notwithstanding the foregoing, the Company shall not be obligated to pay any legal fees or expenses
incurred by the Executive in any contest in which the trier of fact determines that the Executive’s position was frivolous or maintained in bad faith. 

9. Parachute Payments. 

(a) Notwithstanding any other provisions of this Agreement to the contrary, in the event that it shall be determined that any payment or
distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or
otherwise (the “Payments”), would constitute an “excess parachute payment” within the meaning of Section 280G of the Code, the Company shall reduce (but not below zero) the aggregate present value of the Payments
under the Agreement to the Reduced Amount (as defined below), if reducing the Payments under this Agreement will provide the Executive with a greater net after-tax amount than would be the case if no such reduction was made. The Payments shall be
reduced as described in the preceding sentence only if (i) the net amount of the Payments, as so reduced (and after subtracting the net amount of federal, state and local income and payroll taxes on the reduced Payments), is greater than or
equal to (ii) the net amount of the Payments without such reduction (but after subtracting the net amount of federal, state and local income and payroll taxes on the Payments and the amount of Excise Tax (as defined below) to which the
Executive would be subject with respect to the unreduced Payments). Only amounts payable under this Agreement shall be reduced pursuant to this Section 9, and any reduction shall be made in accordance with Section 409A of the Code. 

(b) The “Reduced Amount” shall be an amount expressed in present value that maximizes the aggregate present value of Payments
under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax, determined in accordance 

  
 11 

 
with Section 280G(d)(4) of the Code. The term “Excise Tax” means the excise tax imposed under Section 4999 of the Code, together with any interest or penalties imposed
with respect to such excise tax. 
 (c) All determinations to be made under this Section 9 shall be made by such certified public
accounting firm as may be designated by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the receipt of notice from the Executive
that there has been a Payment, or such earlier time as is requested by the Company. All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any determination by the Accounting Firm shall be binding upon the Company and the
Executive. 
 10. Confidential Information. The Executive shall hold in a fiduciary capacity for the benefit of the Company all
secret or confidential information, knowledge or data relating to the Company or any of the Affiliated Companies, and their respective businesses, which shall have been obtained by the Executive during the Executive’s employment by the Company
or any of the Affiliated Companies and which shall not be or become public knowledge (other than by acts by the Executive or representatives of the Executive in violation of this Agreement). After termination of the Executive’s employment with
the Company, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those
designated by it. In no event shall an asserted violation of the provisions of this Section 10 constitute a basis for deferring or withholding any amounts otherwise payable to the Executive under this Agreement. 

11. Successors. (a) This Agreement is personal to the Executive and without the prior written consent of the Company shall not be
assignable by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives. 

(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. Except as provided in
Section 11(c), without the prior written consent of the Executive this Agreement shall not be assignable by the Company. 
 (c) The
Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the
same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its
business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise. 
 12.
Section 409A. 
 (a) Compliance. This Agreement is intended to comply with the requirements of Section 409A of the
Code, and shall in all respects be administered in accordance with Section 409A of the Code. Notwithstanding anything in the Agreement to the contrary, distributions 

  
 12 

 
may only be made under the Agreement upon a Section 409A “separation from service” or other event permitted by Section 409A, and in a manner permitted by Section 409A of
the Code or an applicable exemption. For purposes of Section 409A of the Code, the right to a series of payments under the Agreement shall be treated as a right to a series of separate payments. The Executive may not, directly or indirectly
designate the calendar year of a payment. 
 (b) Reimbursements. All reimbursements and in-kind benefits provided under the Agreement
shall be made or provided in accordance with the requirements of Section 409A of the Code, including: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses
eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (ii) any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the calendar year
in which the expense was incurred; (iii) any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit; and (iv) reimbursement shall be provided for expenses
incurred during the period specified in this Agreement, or if no such period is specified, during the Executive’s lifetime. If reimbursements are made with respect to outplacement services or outplacement services are provided, such
reimbursements or outplacement services shall be provided in accordance with the requirements of Section 409A, including the requirement that such reimbursements be incurred or services be provided by the end of the second year after the year
in which the Date of Termination occurs and all reimbursement payments be made by the end of the third year after the year in which the Date of Termination occurs. 

(c) Specified Employee. Notwithstanding any provision in this Agreement to the contrary, if the Executive is a “specified
employee” of a publicly traded corporation under Section 409A on the Executive’s Date of Termination and if payment of any amount under this Agreement is required to be delayed for a period of six months after separation from service
pursuant to Section 409A of the Code, payment of such amount shall be delayed as required by Section 409A of the Code, and the accumulated postponed amount shall be paid in a lump sum payment within 10 days after the end of the six-month
period. If the Executive dies during the postponement period prior to the payment of postponed amount, the amounts withheld on account of Section 409A of the Code shall be paid to the personal representative of the Executive’s estate
within 60 days after the date of Executive’s death. A “specified employee” shall mean an employee who, at any time during the 12-month period ending on the identification date, is a “specified employee” under
Section 409A of the Code, as determined by the Compensation Committee of the Board. The determination of “specified employees,” including the number and identity of persons considered “specified employees” and the
identification date, shall be made by the Compensation Committee in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder. 

13. Miscellaneous. 
 (a)
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force
or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. 

  
 13 

 (b) All notices and other communications hereunder shall be in writing and shall be given by hand
delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
 If to
the Executive: 
 Robert K. Beckler 
  

                                         
            
  

                                         
            
 If to the Company: 

MeadWestvaco Corporation 
 501
South 5th Street 
 Richmond, VA 23219-0501 

Attention: Wendell L. Willkie, II 

General Counsel 
 MeadWestvaco
Corporation 
 501 South 5th Street 

Richmond, VA 23219-0501 
 or to such other
address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee. 

(c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement. 
 (d) The Company may withhold from any amounts payable under this Agreement such U.S. federal, state, local
or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation. 
 (e) The Executive’s or the
Company’s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate
employment for Good Reason pursuant to Section 5(c)(i)-(iv) of this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. 

(f) This Agreement, upon its execution, supersedes any other agreement between the parties with respect to the subject matter hereof. The
Executive and the Company acknowledge that, except as may otherwise be provided under any other written agreement between the Executive and the Company, the employment of the Executive by the Company is “at will” and, subject to
Section 2(c) hereof, prior to the Effective Date, the Executive’s employment may be terminated by either the Executive or the Company at any time prior to the Effective Date, in which case the Executive shall have no further rights under
this Agreement; 

  
 14 

 
provided that if it is reasonably demonstrated by the Executive that the Executive’s termination of employment within 30 days before a Change of Control (i) was at the request of a
third party who has taken steps reasonably calculated to effect a Change of Control or (ii) otherwise arose in connection with or anticipation of a Change of Control, then this Agreement shall remain in effect in accordance with
Section 2(c). The Agreement may not be terminated by the Company during the Change of Control Period while the Executive remains an employee of the Company, without the Executive’s consent. 

IN WITNESS WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the authorization from its Board of Directors,
the Company has caused this Agreement to be executed in its name on its behalf, all as of the day and year first above written. 
  

			
	 /s/    Robert K.
Beckler        

	Robert K. Beckler
	
	 MEADWESTVACO CORPORATION

		
	By:	 	 /s/ John A. Luke, Jr.

		 	John A. Luke, Jr.
		 	Chairman and Chief Executive Officer

  
 15 

 EXHIBIT A 

RELEASE 
 In
consideration of the severance benefits offered to me by MeadWestvaco Corporation (the “Company”) under the Employment Agreement dated as of March 3, 2014 (the “Agreement”) and other consideration, I on behalf of myself, and
on behalf of my heirs, administrators, representatives, successors, and assigns (the “Releasors”), hereby release acquit and forever discharge the Company, all of its past, present and future subsidiaries and affiliates and all of their
respective directors, officers, employees, agents, trustees, partners, shareholders, consultants, independent contractors and representatives, all of their respective heirs, successors, and assigns and all persons acting by, through, under or in
concert with them (the “Releasees”) from any and all claims, charges, complaints, obligations, promises, agreements, controversies, damages, remedies, demands, actions, causes of action, suits, rights, costs, debts, expenses and
liabilities that the Releasors might otherwise have asserted arising out of my employment with the Company and its subsidiaries and affiliates, including the termination of that employment. 

However, the Releasors are not releasing any rights under (i) any qualified employee retirement plan, (ii) any claim for
compensation and benefits to be provided to me under the Agreement, (ii) any claim for vested benefits or benefits that I am otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the
Company or any of the Affiliated Companies at or subsequent to the Date of Termination, (iii) any claim related to my indemnification as an officer, director and employee of the Affiliated Companies under the Company’s Certificate of
Incorporation or By-Laws, or (iv) any rights or claims that may arise after the date on which I sign this release (the “Release”). Those rights shall survive unaffected by this Release. 

I understand that, as a consequence of my signing this Release, I am giving up, any and all rights I might otherwise have with respect to my
employment and the termination of that employment including but not limited to rights under (1) the Age Discrimination in Employment Act of 1967, as amended; (2) any and all other federal, state, or municipal laws prohibiting
discrimination in employment on the basis of sex, race, national origin, religion, age, handicap, or other invidious factor, or retaliation; and (3) any and all theories of contract or tort law related to my employment or termination thereof,
whether based on common law or otherwise. 
 I acknowledge and agree that: 

A. The benefits I am receiving under the Agreement constitute consideration over and above any benefits that I might be entitled to receive
without executing this Release. 
 B. The Company advised me in writing to consult with an attorney prior to signing this Release. 

C. I was given a period of at least twenty-one (21) days within which to consider this Release; and 

D. The Company has advised me of my statutory right to revoke my agreement to this Release at anytime within seven (7) days of my signing
this Release. 

  
 A-1 

 I warrant and represent that my decision to sign this Release was (1) entirely voluntary on
my part; (2) not made in reliance on any inducement, promise, or representation, whether express or implied, other than the inducements, representations, and promises expressly set forth herein and in the Agreement and (3) did not result
from any threats or other coercive activities to induce my agreement to this Release. 
 If I exercise my right to revoke this Release
within seven (7) days of my execution of this Release, I warrant and represent that I will: (1) notify the Company in writing, in accordance with the attached Agreement, of my revocation of this Release, and (2) simultaneously return
in full any consideration received from the Company or any employee benefit plan sponsored by the Company. 
 The parties agree that this
release shall not affect the rights and responsibilities of the US Equal Employment Opportunity Commission (hereinafter “EEOC”) to enforce the Age Discrimination in Employment Act of 1967, as amended and other laws. In addition, the
parties agree that this release shall not be used to justify interfering with my protected right to file a charge or participate in an investigation or proceeding conducted by the EEOC. The parties further agree that the Releasors knowingly and
voluntarily waive all rights or claims that arose prior to the date hereof that the Releasors may have against the Releasees to receive any benefit or remedial relief (including, but not limited to, reinstatement, back pay, front pay, damages,
attorneys’ fees, experts’ fees) as a consequence of any investigation or proceeding conducted by the EEOC. 
 The provisions of
this Release are severable, and if any part of it is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable. This Release shall be construed in accordance with its fair meaning and in accordance with the laws of the
State of Delaware, without regard to conflicts of laws principles. Capitalized terms used but not defined herein shall have the meanings set forth in the Employment Agreement. 

I further warrant and represent that I fully understand and appreciate the consequences of my signing this Release. 

 

			
	Name:	 	  

		 	(Please Print)
		
	Signature:	 	  

		
	Date:	 	  

  
 A-2EX-10.3

 Exhibit 10.3 

Eric N. Prystowsky, M.D. 

CONSULTING AGREEMENT 
 This
CONSULTING AGREEMENT (this “Agreement”) is made by and between STEREOTAXIS, INC., a Delaware corporation (hereinafter “Company”), and ERIC N. PRYSTOWSKY,
M.D., an individual (hereinafter “Consultant”), effective as of the last date signed by the parties (the “Effective Date”). 

WHEREAS, Consultant is affiliated with St. Vincent’s Health System (hereinafter “Institution”) and is affiliated with Ascension
Health (hereinafter “Ascension”). Consultant has been involved in medical research in fields of particular interest to the Company and has achieved recognition as an international leader in the field of electrophysiology. The Company
wishes to retain Consultant in a consulting capacity and Consultant desires to perform such consulting services. 
 WHEREAS, the Company has
developed and acquired substantial information and expertise in the Field of Interest, with or without the use of Company Technology, and will disclose to Consultant such information as Company deems appropriate in connection with the consulting
services to be furnished by Consultant. 
 NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration,
the adequacy and receipt of which are hereby acknowledged, the parties agree as follows: 
 1. Definitions. 

1.1 Field of Interest means computer-controlled or assisted navigation and delivery systems for interventional disposable devices, with
or without the use of magnetic devices or systems, and related interventional workstations, devices, and integrated information networks, used in or with interventional medical procedures. 

1.2 Company Technology means all information, data, equipment, devices, inventions, discoveries, trade secrets, know-how, software,
hardware, and associated intellectual property rights in the Field of Interest that are owned, developed, or licensed to or by the Company. 

1.3 US means the United States of America. 

2. Services. Consultant shall advise the Company’s management, employees, and agents, at reasonable times, in matters related to the Field
of Interest, as requested by the Company. In response to a request by an officer or duly appointed representative of the Company, Consultant shall provide consultation over the telephone, in person at Consultant’s office, or through written
correspondence. Such consultation will include reviewing activities and developments in the Field of Interest and advising on new products and applications for the Company Technology. In addition, Consultant shall, from time-to-time, make himself
available in person at the Company’s offices or other locations as agreed upon by the parties. The consulting services (“Services”) required under this Section 2 are described in greater detail on Exhibit A,
attached hereto and incorporated herein by reference. 

 3. Consideration. 

3.1 In consideration for the Services provided by Consultant under Section 2 hereof, Consultant will be compensated as described below:

 (a) The Company agrees to pay Consultant US $600.00 per hour in consideration of Consultant’s provision of the Services described in
Section 2 hereof at the specific request of the Company, and shall be limited to such amount of time as the parties may agree in advance. The parties agree that the number of hours to be provided by Consultant pursuant to this Agreement on an
annual basis shall be deemed to be as listed on Exhibit A to this Agreement. Company shall have no obligation to make payment unless and until Consultant shall have submitted his invoice for the applicable month. The Company shall not
reimburse for time and/or services otherwise billable to insurance carriers or other third parties. Consultant shall also complete and submit the attached W-9 to the Company. 

(b) The Company agrees to reimburse Consultant for reasonable and documented travel and related expenses actually incurred by Consultant and
pre-approved in writing by the Company, in accordance with Company standard expense reimbursement policies, as amended from time to time. Consultant shall also maintain records of his actual expenses incurred in connection with the performance of
the Services under the Agreement. 
 (c) Within thirty (30) days following the end of each month, Consultant shall submit to Company
invoices for the Services performed, including a pro rata monthly portion of the deemed hours for the Services set forth on Exhibit A for such month, and the Company shall pay the applicable amount sixty (60) days following
receipt of such invoice or otherwise in accordance with the Company’s standard payment cycle. 
 3.2 Consultant acknowledges and agrees
that the fees and expenses provided for above represent Company’s full and complete obligation for any and all advisory and consulting services to be rendered, and expenses incurred, by Consultant under this Agreement. 

3.3 The Company and Consultant acknowledge and agree that the consideration set forth in this Section 3 represents the fair market value
for the Services to be rendered under this Agreement, and no amount payable hereunder is intended to constitute a payment for the inducement of patient referrals, the purchase, lease, or order of any item or service, or the recommending or arranging
for the purchase, lease, or order of any item or service. 
 4. Term and Termination. 

4.1 This Agreement shall have a term of one (1) year from the Effective Date (the “Term”). Thereafter, the parties may renew the
Agreement for additional successive periods of one (1) year each at the expiration of the Term or any renewal term by written amendment to this Agreement. In the event the parties decide to renew this Agreement, in each instance, Consultant and
the Company shall mutually agree upon a new Exhibit A for the services Consultant will provide during such renewal Term. 
 4.2
This Agreement may be terminated by the parties as follows: 
  

	 	(a)	Either party may terminate this Agreement immediately in the event of a material breach of any term or condition of this Agreement by the other party that is not cured within thirty (30) days after written notice
is provided by the non-breaching party. 

  
 Page 2 of 11 

	 	(b)	Either party may immediately terminate this Agreement upon written notice to the other party in the event the other party makes a general assignment for the benefit of creditors, or files a voluntary petition in
bankruptcy, or if a decree is entered involuntarily adjudicating such other party bankrupt and such decree is not dissolved within sixty (60) days, or if a receiver shall be appointed for all the property of such other party and shall not be
discharged within sixty (60) days. 

  

	 	(c)	Either party may, with or without cause, terminate this Agreement by giving at least thirty (30) days prior written notice of such termination to the other party. 

4.3 Any termination hereof shall not waive any legal or equitable remedy available to the non-breaching party against the breaching party by
reason of such breach. In the event of a termination of this Agreement pursuant to this Section, the parties shall not enter into any new agreements or financial arrangements with respect to the subject matter hereof from the date of termination
until the next anniversary date of the Effective Date. 
 4.4 Upon termination, all accrued payment obligations for Services as of the date
of the notice of termination will be paid by the Company. 
 5. Certain Other Contracts. 

5.1 Consultant will not disclose to the Company any information that Consultant is obligated to keep secret pursuant to an agreement with, or
other duty of confidentiality to, a third party, and nothing in this Agreement shall be deemed to impose any obligation on Consultant to the contrary. In the event that either party has a contractual or ethical obligation to disclose the existence
of this Agreement to a third party the other party hereby consents to such disclosure, provided that the disclosing party notifies the other party prior to such disclosure. 

5.2 Consultant shall not use the time, funding, resources, or facilities of the Institution, Ascension or any other third party to perform
Services hereunder, and Consultant shall not perform the Services hereunder in any manner that would give the Institution, Ascension or any third party any claim of benefit to, or rights (including intellectual property rights) in the product of
such Services. If Consultant will use the resources or facilities of Institution, Ascension or other third parties for the hosting of site visits or other consulting activities, Consultant shall obtain the necessary prior permissions from the
respective third parties for use of such resources or facilities. 
 5.3 Consultant has disclosed on Schedule 5.3, attached
hereto and incorporated herein by reference, all present, and during the Term of this Agreement Consultant shall promptly disclose to the General Counsel of the Company (or such other person as may be designated by the Company) any subsequent,
actual or potential conflicts between this Agreement and any other agreements between Consultant and any third party, including any such agreements relating to the Field of Interest. 

6. Exclusive Services. Consultant agrees that during the Term of this Agreement and for a period ending one year after the expiration or earlier
termination of this Agreement pursuant to Section 4 or otherwise, he will not directly or indirectly either (i) provide any consulting, education, advisory, development, and clinical research or other services to any other business

  
 Page 3 of 11 

 
or commercial entity for the purpose of advancing the ability of such other business or commercial entity to compete with the Company in the Field of Interest, or (ii) participate in the
formation of any business or commercial entity which competes with the Company in the Field of Interest. 
 7. Disclosure of Discoveries to the
Company. Subject to Consultant’s confidentiality obligations to third parties, during the Term Consultant will use his best efforts to disclose to the Vice President, Research and Development of the Company (or such other person as may
be designated by the Company), on a confidential basis, technology and product opportunities which come to the attention of Consultant in the Field of Interest, and any idea, concept, invention, improvement, discovery, process, formula, technique,
or method, or other intellectual property relating to, or useful in, the Field of Interest, whether or not patentable or copyrightable (hereinafter “Discoveries”). 

8. Consultant Discoveries. Consultant will promptly and fully disclose to the Vice President, Research and Development of the Company (or such
other person as may be designated by the Company) any Discoveries conceived, developed, or first reduced to practice by Consultant or by the Institution, Ascension or anyone working on their respective behalves, either alone or jointly with others,
while performing Services pursuant to this Agreement (the “Consultant Discoveries”). Consultant agrees to, and hereby does, assign to the Company all of his right, title, and interest in and to any such Consultant Discoveries. Consultant
agrees to take such actions and execute such documents as reasonably required by Company to secure and enforce Company’s rights in Consultant Discoveries, including the documents required for Company to apply for, obtain, and enforce patents or
copyrights in any and all countries on such Consultant Discoveries. Consultant hereby irrevocably designates the Secretary of the Company as his agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary to
apply for and obtain patents and copyrights, and to enforce the Company’s rights under this Section. This Section 8 will survive the termination of this Agreement with respect to Consultant Discoveries. Without limiting the foregoing, but
subject to Consultant’s rights in Section 11 hereof, the Company shall have the exclusive right to use and exploit economically, to divulge, to publish, to record, to translate, to distribute, and to modify all the papers, publications,
and any other document or information relating to Company Technology or otherwise within the Field of Interest. The documents, papers, and other information (including such Consultant Discoveries) shall not be transferred, communicated to third
parties, divulged, or published for any reason without the Company’s prior written consent. 
 9. Health Information. The parties
recognize a common goal of securing the integrity of all individually identifiable health information and according that information the highest possible degree of confidentiality and protection from disclosure. The parties shall comply with all
applicable state and federal laws and regulations including the privacy and confidentiality of patient records including but not limited to (i) The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”); (ii) the
Privacy and Security Standards (45 C.F.R. Parts 160 and 164) and the Standards for Electronic Transactions (45 C.F.R Parts 160 and 162) (collectively, the “Standards”) promulgated or as to be promulgated by the Secretary of Health and
Human Services on and after the applicable effective dates specified in the Standards; and (iii) The Health Information Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”). The parties shall also comply with all
applicable rules, regulations, and policies regarding the confidentiality and privacy of protected health information and individually identifiable health information as provided by HIPAA and the regulations promulgated pursuant thereto
(collectively, “PHI”). Consultant agrees to report to the Company’s designated privacy officer any known or suspected privacy breach of unsecured PHI or any use or disclosure of PHI in violation of this Agreement in accordance with
applicable Company’s Policies. The parties shall cooperate in the investigation and resolution of any reports of suspected violations of HIPAA. 

  
 Page 4 of 11 

 10. Confidentiality. 

10.1 Consultant acknowledges that, during the course of performing Services pursuant to this Agreement, the Company will be disclosing
confidential information to Consultant, and that Consultant may develop information, related to the business of the Company, including but not limited to, Discoveries, Consultant Discoveries, projects, products, prospective suppliers, prospective
customers, personnel, business plans, and finances, as well as other commercially valuable information (hereinafter “Company Information”). Consultant acknowledges that the Company’s business is extremely competitive, dependent in
part upon the maintenance of secrecy, and that any improper disclosure of the Company Information would result in serious and irreparable harm to the Company. 

10.2 Consultant agrees that Consultant shall only use Company Information in connection with providing Services to Company hereunder, and that
Consultant shall not use the Company Information in any way that is detrimental to the Company. 
 10.3 Consultant shall not disclose,
directly or indirectly, Company Information to any third person or entity, other than to representatives or agents of the Company without the Company’s consent. Consultant will treat Company Information as confidential and the proprietary
property of the Company. 
 10.4 Nothing in this Agreement shall prevent Consultant from disclosing or using information that: 

(a) Consultant can prove by documentary evidence was already in his possession and at his free disposal before the disclosure to him hereunder;
or 
 (b) is subsequently disclosed to Consultant by a third party not under any obligations of confidentiality to the Company; or 

(c) is or becomes generally available to the public through no fault of Consultant; or 

(d) is independently developed by Consultant without the use of Company Information; or 

(e) is required by law to be disclosed by Consultant, subject to Section 10.5 below. 

10.5 Consultant may disclose Company Information hereunder solely to the extent such disclosure is reasonably necessary in connection with
submissions to any governmental authority in connection with this Agreement or in filing or prosecuting patent applications contemplated under this Agreement, prosecuting or defending litigation, complying with applicable laws or for the purposes
expressly permitted by this Agreement; provided that in the event of any such disclosure of the Company Information by Consultant, Consultant will, except where impracticable, give reasonable advance notice to the Company of such disclosure
requirement so that the Company may seek a protective order and or other appropriate remedy or waive compliance with the confidentiality provisions of this Section 10, and will reasonably cooperate with the Company in any efforts to secure
confidential treatment of such Company Information required to be disclosed. 

  
 Page 5 of 11 

 10.6 Whenever requested by Company, Consultant will promptly return to the Company all materials
containing or reflecting Company Information as well as data, records, reports, and other property, furnished by the Company to Consultant or produced by Consultant in connection with Services rendered hereunder, together with all copies of any of
the foregoing. Notwithstanding such return, Consultant shall continue to be bound by the terms of the confidentiality provisions contained in this Section 10 for a period of four (4) years after the expiration or termination of this
Agreement. 
 11. Publication. The Company acknowledges that Consultant, Institution and Ascension are dedicated to a free scholarly exchange
and to public dissemination of the results of their scholarly activities. Except as otherwise agreed below, nothing in this Agreement shall restrict the right of Consultant to publish, disseminate, or otherwise disclose information about work
conducted pursuant to this Agreement. 
 Consultant shall not publish or present any reports, abstracts, articles, or data compilations of
or pertaining to work performed at the request of Company under this Agreement without providing Company thirty (30) days’ prior written notice of the publication/presentation date and the text of the proposed publication/presentation so
that Company may review it and submit comments. Consultant agrees to consider in good faith any comments reasonably requested by Company prior to publication or presentation. In addition, Consultant shall delay any proposed
publication/presentation an additional sixty (60) days in the event Company so requests in order to enable the Company to secure patent or other proprietary protection for any invention(s) disclosed in such publication/presentation to the
extent owned by Company. This obligation shall survive termination of this Agreement. In accordance with FDA regulations and the Company’s Quality System (as defined by FDA regulations), publications co-authored by the Company
personnel that are defined as labeling or advertising under current FDA guidelines, as determined at the sole discretion of the Company, are subject to the Company’s document review and approval process prior to submission for publication, and
shall, if appropriate, be amended by Consultant to conform to such guidelines. The document review and approval process shall be completed within the aforementioned thirty (30) day period.

12. Use of Name. 
 12.1 Neither
party shall use the name of the other for any commercial purpose without the prior written consent of the named party for the specific use. 

12.2 Notwithstanding the foregoing, Consultant understands that his name and his affiliation with the Institution and/or Ascension may appear
in disclosure documents required by securities laws, and in other US or other applicable non-US regulatory and administrative filings in the ordinary course of the Company’s business. The foregoing uses in this Section 12.2 will be deemed
to be non-commercial uses. 
 13. Consultant Representations, Warranties and Covenants. Consultant represents and warrants to the Company
that: 
 (a) he is free to enter into this Agreement and that neither this Agreement nor the performance of Consultant’s obligations
hereunder present actual or potential conflicts with any other agreements, understandings, policies, or other arrangements (including, without limitation, of the Institution and Ascension) under which Consultant owes any duties or obligations,
including any agreements, understandings, policies or other arrangements that Consultant has with any person or firm relating to the Field of Interest; and 

  
 Page 6 of 11 

 (b) neither the execution of this Agreement nor the performance of Consultant’s obligations
under this Agreement will result in a violation or breach of any other obligation of confidentiality or any employment, consulting, advisory, development, or other agreement by which Consultant is bound (including with respect to the Institution and
Ascension) or, to Consultant’s knowledge, of any U.S. or applicable non-U.S. law or regulation. 
 14. Disclosure of Agreement. In
conjunction with the representations under Section 13 above, Consultant further represents that he has informed Institution and Ascension of the existence of this Agreement. 

15. Disclosure of Fees and Services. Consultant acknowledges and agrees that all consulting arrangements and the Company’s relationship
with Consultant and/or Institution or Ascension are subject to public disclosure in Company communications, including on the Company’s website. Such disclosure may include, but is not limited to, compensation paid to Consultant, Institution or
Ascension for services, payments for travel expenses (lodging, transportation, and meals), consulting fees, royalties, equity, discounts, rebates, and/or intellectual property terms. 

16. Notices. All notices, requests or other communications to a party will be sufficient if contained in a written instrument, addressed to such
party at the address set forth below or such other address as may be designated in writing by the addressee to the addresser, if: delivered in person, or sent by overnight courier with record of receipt, or sent by fax or email, with receipt
acknowledged by the below-named addressee or its authorized designee. 
 In the case of the Company: 

Stereotaxis, Inc. 
 4320 Forest
Park Avenue, Suite 100 
 St. Louis, Missouri 63108 

Attention: General Counsel 

Email : karen.duros@stereotaxis.com 

Fax: 314-667-3448 
 In the case
of Consultant: 
 Dr. Eric N. Prystowsky 

958 Laurelwood 
 Carmel, IN
46032 
 Email:
                         

or to such other address as may have been designated by the Company or Consultant by notice to the other given as provided herein. 

17. Independent Contractor; Withholding. Consultant will at all times be an independent contractor, and as such will not have authority to bind
the Company or commit Company or any affiliate of Company to any legal obligation whatsoever, or to hire or retain other parties at Company expense, without Company’s prior written approval. Consultant shall not enter into any agreements or
incur any obligations on behalf of the Company. While on Company 

  
 Page 7 of 11 

 
premises, Consultant shall comply strictly with all laws and regulations, take all safety precautions, and follow all of Company’s safety and operating rules. Consultant will not act as an
agent nor shall Consultant be deemed to be an employee of the Company for the purposes of any employee benefit program, unemployment benefits, or otherwise. Consultant recognizes that no amount will be withheld from his compensation for payment of
any federal, state, or local taxes and that Consultant has sole responsibility to pay such taxes, if any, and file such returns as shall be required by applicable laws and regulations. 

18. Performance of Services. Consultant shall perform the Services to the best of his ability and in accordance with the degree of skill, care,
and diligence normally exercised by recognized professional persons or firms that supply services of a similar nature. If Consultant considers that any information, documents, or other particulars made available by Company are not sufficient to
enable the Consultant to provide the Services in accordance with this Agreement, the Consultant shall advise Company which shall then provide such further assistance, information, or other particulars as Company deems necessary. Consultant shall
give immediate written notice to Company of any fact, matter, or thing that may affect the Consultant’s ability to provide the Services. Consultant represents that he has secured all necessary licenses, certificates, and permits required to
perform Services pursuant to this Agreement. 
 19. Assignment. Due to the personal nature of the Services to be rendered by Consultant,
Consultant may not assign this Agreement. The Company may assign all rights and liabilities under this Agreement to a subsidiary or an affiliate or to a successor to all or a substantial part of its business and assets without the consent of
Consultant. Subject to the foregoing, this Agreement will inure to the benefit of and be binding upon each of the heirs, assigns, and successors of the respective parties. 

20. Severability and Modification Upon Triggering Event. This Agreement shall be construed to the fullest extent possible to be in compliance
with and permitted by all US, non-US, state, or other local laws, statutes, rules, and regulations. If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, such provision shall be severed and the remaining provisions
shall continue in full force and effect. Notwithstanding the foregoing, if a Triggering Event (as defined below) occurs after the date hereof, the parties agree that they shall amend this Agreement solely to the extent necessary to comply with the
item giving rise to the Triggering Event, and in a manner that shall preserve the underlying economic and financial arrangements between the parties with the least changes to the parties’ expectations hereunder. For purposes of this
Section 20, a “Triggering Event” shall mean any U.S., state, or local governmental agency, or any other non-US local governmental agency, or any court or administrative tribunal, passing, issuing, or promulgating any law, final rule,
final regulation, or rendering from an evidentiary proceeding any order, decision, or judgment (including but not limited to those relating to any final regulations or administrative interpretations promulgated under applicable anti-kickback or
self-referral statutes) which in the good faith and reasonable judgment of a party hereto materially and adversely affects such party’s licensure or certification, ability to obtain any material benefit hereunder or under any payment program to
which it is a party or ability to perform a material obligation hereunder, or renders this Agreement unlawful. If the parties in good faith cannot agree on a necessary amendment under this Section 20 within thirty (30) days of notification
of the Triggering Event, then this Agreement shall terminate without further action on the 30th day. 

  
 Page 8 of 11 

 21. Remedies. Consultant acknowledges that the Company would have no adequate remedy at law to
enforce Sections 6, 8, and 10 hereof. In the event of a violation by Consultant of such Sections, the Company shall have the right to obtain injunctive or other similar relief, as well as any other relevant damages, without the requirements of
posting bond or other similar measures. 
 22. Governing Law. This Agreement shall be interpreted, and the rights of the parties determined in
accordance with the substantive laws of the State of Missouri, US, without regard to conflicts of laws principles. 
 23. Entire Agreement.
This Agreement sets forth the entire understanding of the parties with respect to the subject matter herein, and supersedes all prior agreements between the parties. 

24. Modifications. This Agreement may only be amended in writing, specifically referencing this Agreement and signed by both Company and
Consultant. No amendments shall be valid without endorsement by a Company Compliance Officer. 
 25. Counterparts. This Agreement may be
executed by the parties hereto in separate counterparts, by facsimile transmission or by e-mail delivery of a “.pdf” format data file, each of which when so executed shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement. 
 [Remainder of page intentionally left blank. Signatures follow.] 

  
 Page 9 of 11 

 COUNTERPART SIGNATURE PAGE TO THE 

CONSULTING AGREEMENT 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

COMPANY: 
 STEREOTAXIS, INC. 

 

			
	 BY:
	 	 /s/ Karen Witte Duros

	 Name:
	 	Karen Witte Duros
	 Title:
	 	Sr. VP and General Counsel
		 	Clinical Compliance Officer

 DATE: June 4, 2014 

This Agreement is not valid without endorsement by a Stereotaxis Compliance Officer. 

CONSULTANT: 
  

			
	SIGNED:	 	/s/ Eric N. Prystowsky
	Printed Name: Eric N. Prystowsky, M.D.

 DATE: June 3, 2014 

 Exhibit A 

Description of Consulting Services 
  

					
	 	  	Hours on
Annual Basis	 
	 Speaking/moderation role at scientific conferences*
	  			
	 - AF Symposium
	  	 	4	  
	 - HRS
	  	 	1	  
	 - Other conferences
	  	 	6	  
	 Clinical research & publication strategy*
	  	 	10	  
	 Product roadmap advisory*
	  	 	10	  
	 Board education on AF treatment*
	  	 	4	  
		  	  
	  
	 
	 Total
	  	 	35	  

  

	*	The parties agree that the number of hours to be provided by Consultant for the Services pursuant to this Agreement on an annual basis shall be deemed to be as listed above. For each month, Consultant shall be deemed to
have provided a pro rata monthly portion of the deemed hours for these Services set forth above.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]